Q-omics provides the consensus-scored MIR3619 profile across patient tissues and cancer cell-line models. MIR3619 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, MIR3619 is differentially expressed in 3, with the highest sampling consensus in STAD. Additionally, MIR3619 RNA expression shows 10,277 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LUSC, STAD, and GBM as cancer lineages where MIR3619 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR3619 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR3619 survival associations across molecular data types. MIR3619 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR3619 RNA expression–survival associations across cancer types. High MIR3619 expression shows unfavorable associations in LUSC, LIHC, MESO, LAML and STAD, but favorable associations in ESCA. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for MIR3619 RNA expression.
This table summarizes MIR3619 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in PRAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR3619. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR3619 shows lower tumor expression in KICH and higher tumor expression in STAD and PRAD. The STAD box plot shows higher MIR3619 RNA expression in tumor versus normal tissue (log2 FC = +0.340, t-test p = .011).
This table shows molecular features associated with MIR3619 in patient tissues and cancer cell lines. In patient samples, MIR3619 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
